logo
AI can tell how old your body really is and how quickly you're aging using just a selfie

AI can tell how old your body really is and how quickly you're aging using just a selfie

Yahoo11-05-2025

When you buy through links on our articles, Future and its syndication partners may earn a commission.
A new artificial intelligence (AI) model can predict a person's biological age — the state of their body and how they're aging — from a selfie.
The model, dubbed FaceAge, estimates how old a person looks compared to their chronological age, or the amount of time that's passed since their birth. FaceAge's makers say their tool could help doctors decide on the best course of treatment for diseases like cancer. But one outside expert told Live Science that before it is used that way, follow-up data needs to show it actually improves treatment outcomes or quality of life.
When a doctor is treating a cancer patient, "one of the first things they do is they try to assess how well the individual is doing," Hugo Aerts, director of the AI in Medicine Program at Mass General Brigham, said in a news briefing on May 7. "This is often a very subjective assessment, but it can influence a lot of future decisions" about their treatment, including how aggressive or intense their treatment plan should be, he added. For example, doctors may decide a patient who looks younger and more fit for their age may tolerate an aggressive treatment better and eventually live longer than a patient who looks older and more frail, even if the two have the same chronological age.
FaceAge could make that decision easier by turning doctors' subjective estimates into a quantitative measure, the study authors wrote in the new study published May 8 in the journal Lancet Digital Health. By quantifying biological age, the model could offer another data point in helping doctors decide which treatment to recommend.
Aerts and his colleagues trained the model on more than 58,000 photos of people ages 60 years and older who were assumed to be of average health for their age at the time the photo was taken. In this training set, the researchers had the model estimate chronological ages and assumed that the people's biological ages were similar, though the scientists noted that this assumption is not true in every case.
The team then used FaceAge to predict the ages of more than 6,000 people with cancer. Cancer patients looked about five years older, on average, than their chronological ages, the team found. FaceAge's estimates also correlated with survival after treatment: The older a person looked, regardless of their chronological age, the lower their chances of living longer. By contrast, chronological age was not a good predictor of survival in cancer patients, the team found.
FaceAge isn't ready for hospitals or physicians' offices yet. For one, the dataset used to train the model was pulled from IMDb and Wikipedia — which may not represent the general population, and may also not account for factors like plastic surgery, lifestyle differences, or images that have been digitally retouched. Further studies with larger and more representative training sets are needed to understand how those factors impact FaceAge estimations, the authors said.
And the researchers are still improving the algorithm with additional training data and testing its efficacy for other conditions besides cancer. They're also investigating what factors the model draws on to make its predictions. But once it's finalized, FaceAge could, for example, help doctors tailor the intensity of cancer treatments like radiation and chemotherapy to specific patients, study co-author Dr. Ray Mak, a radiation oncologist at Mass General Brigham, said during the briefing. A clinical trial for cancer patients, comparing FaceAge to more traditional measures of a patient's frailty, is starting soon, Mak added.
RELATED STORIES
—Sped-up 'biological aging' linked to worse memory
—New tool estimates your immune 'age,' predicts risk of disease
—Will humans ever be immortal?
Ethical guidelines surrounding how FaceAge information can be used, such as whether health insurance or life insurance providers could access FaceAge estimates to make coverage decisions, should be established before rolling out the model, the researchers said. "It is for sure something that needs attention, to assure that these technologies are used only for the benefit of the patient," Aerts said in the briefing.
Doctors would also need to carefully consider when and how they use FaceAge in clinical settings, said Nicola White, a palliative care researcher at University College London who was not involved in the study. "When you're dealing with people, it's very different to dealing with statistics," White told Live Science. A long-term study assessing whether involving FaceAge in treatment decisions improved patients' quality of life is needed, she said.
The researchers noted the AI tool wouldn't be making calls about treatment on its own. "It's not a replacement for clinician judgement," Mak said. But FaceAge could become part of a physician's toolkit for personalizing a treatment plan, "like having another vital sign data point."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Coherus BioSciences, Inc. (CHRS): A Bull Case Theory
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory

Yahoo

time43 minutes ago

  • Yahoo

Coherus BioSciences, Inc. (CHRS): A Bull Case Theory

We came across a bullish thesis on Coherus BioSciences, Inc. (CHRS) on Steve Wagner's Substack. In this article, we will summarize the bulls' thesis on CHRS. Coherus BioSciences, Inc. (CHRS)'s share was trading at $0.77 as of 30th May. CHRS's trailing P/E was 1.77 according to Yahoo Finance. Scientist in a lab working on a research project, focusing on biotechnology and healthcare advancements. Coherus BioSciences (CHRS), long overlooked by Wall Street, is taking a bold step into innovative oncology by partnering with UK-based STORM Therapeutics to test a novel cancer treatment strategy. The collaboration brings together Coherus's immunotherapy toripalimab (LOQTORZI) and STORM's first-in-class RNA-modifying enzyme inhibitor STC-15 in a Phase 1b/2 clinical trial. This unexpected pairing represents a fresh approach to immuno-oncology, targeting cancer through dual mechanisms that could produce synergistic effects. Toripalimab, already approved in the U.S. for nasopharyngeal carcinoma and under review for broader indications, offers proven checkpoint inhibition, while STC-15 introduces a cutting-edge method of disrupting RNA methylation processes linked to tumor growth and immune evasion. If this combo demonstrates efficacy, it could represent a completely new class of cancer therapy and place Coherus at the forefront of next-generation immuno-oncology innovation. Importantly, this partnership shows strategic vision from CHRS's management as they seek to differentiate the company beyond biosimilars and move deeper into proprietary immunotherapy. With the trial still in early stages and little market attention so far, the risk/reward profile for investors is potentially skewed to the upside. Should the data prove positive, the impact could be significant for both companies, especially for CHRS as it repositions itself as a serious player in oncology innovation. This under-the-radar development deserves close monitoring, as it could catalyze a major reevaluation of Coherus's valuation and growth trajectory. Previously, we have covered CHRS in March 2025 wherein we summarized a by the same author. Coherus BioSciences (CHRS) posted a strong turnaround in 2024 with $267M in revenue and $28.5M net income, driven by Loqtorzi's growth and the planned $250M Udenyca divestiture. The company pivoted fully to oncology, trimmed costs, and advanced its pipeline, yet management expressed frustration over the stock's undervaluation, hinting at potential M&A. Since our last coverage, the stock is down 38% as of 30th May. We don't trust CHRS' management as the stock lost more than 95% of its value in recent years and is still losing a ton of money. The market agrees with us and thinks this stock is going to go bankrupt. We believe CHRS should stop wasting shareholder's money, sell valuable assets, and liquidate the company. We don't think that's a likely outcome. Coherus BioSciences, Inc. (CHRS) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 10 hedge fund portfolios held CHRS at the end of the first quarter which was 10 in the previous quarter. While we acknowledge the potential of CHRS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Morgantown Heart Walk raises $90K to fight heart disease in West Virginia
Morgantown Heart Walk raises $90K to fight heart disease in West Virginia

Yahoo

timean hour ago

  • Yahoo

Morgantown Heart Walk raises $90K to fight heart disease in West Virginia

MORGANTOWN, (WBOY) — On Sunday morning, the American Heart Association held its annual Heart Walk in Morgantown, raising more than $90K for West Virginia patients facing heart disease and other heart-related health problems. Held at the Mylan Park Aquatics Center track, hundreds of walkers (and several pets) gathered to raise money for and raise awareness of heart disease, the leading cause of death in the United States, according to the Centers for Disease Control and Prevention (CDC). Lauren Thomas, the Development Director for the American Heart Association in the Morgantown area, told 12 News that making people aware of things they can do to reduce their risk of heart disease and stroke is an important step to reducing those numbers. 'Today is all about bringing awareness to heart health and heart disease. It's the number one killer of Americans, and stroke is the number five killer of Americans,' Thomas said. 'It's all about how we can prevent that from happening, and also celebrating our survivors that it has happened to, and honoring those that we've lost.' Mon Health Disease Management Specialist Chris Hedio said that common symptoms of heart disease can range from tiredness, lethargy, higher blood pressure or a higher risk of stroke. However, even if you are diagnosed with heart disease, there are several simple things a person can do to reduce the severity of future health issues. WATCH: Mama bear and cubs spotted in Bridgeport backyard 'Some people with heart disease have the misconception that once they're diagnosed that they can't do anything to help treat it or help reverse it on their own and that they have to go to a doctor, they have to have surgery or some type of procedure, when really, a lot of times if you just excercise more, eat right, follow what your doctor is telling you to do, you can live a very long time without any issue,' Hedio said. As of this publication, the Greater Morgantown Area Heart Walk has raised $90,830, with the goal of raising $110,000. If you would like to donate to the Morgantown Heart Walk fundraiser, you can visit this page of the American Heart Association website. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

2 Iowa teens attend Type 1 diabetes Children's Congress in Washington, D.C.
2 Iowa teens attend Type 1 diabetes Children's Congress in Washington, D.C.

Yahoo

timean hour ago

  • Yahoo

2 Iowa teens attend Type 1 diabetes Children's Congress in Washington, D.C.

DES MOINES, Iowa — Two teenagers from Iowa joined youth from across the world at the Breakthrough T1D Children's Congress in Washington, D.C. this weekend. Every two years, the Children's Congress brings youth from across the world to Washington D.C. to share their Type 1 diabetes stories with Federal lawmakers. This year, the delegates are visiting from June 7 -9 and represent Breakthrough T1D groups across all 50 states, Australia, Canada, Israel, the Netherlands, and the United Kingdom. Greek Food Fair Festival helps keep Church in community The youth will act as delegates who share their stories and the stories of others, while engaging in leadership and advocating for continued research funding. This year, two delegates from Iowa, Elizabeth and Sachin, are sharing their stories. Elizabeth, 17, is from Adel and was diagnosed with T1D at 14 years old, just days before the Super Bowl. She says seeing Noah Grey on the field reminded her that she could do anything. Elizabeth has built a T1D community through sharing tips and tricks, and hopes it helps others feel less alone. Elizabeth enjoys connecting with the community through her job and volunteering, she hopes to open her own business in the future. Sachin, 13, was diagnosed with T1D at 10 and loves everything engineering. Sachin enjoys making fun inventions that bring laughter, and practical ones like a new kind of insulin pump he designed for his recent science fair project. Since his diagnosis, Sachin has attended walks, galas, and summits to support Breakthrough T1D and learn about exciting new technology that could help those living with Type 1 diabetes. Visit the Breakthrough T1D website to learn more about the Children's Congress and the 170 delegates. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store